NovaBay Pharmaceuticals, Inc.
NBY · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -6.4% | -27.4% | 41.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 66.3% | 58.2% | 54% | 63.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -60.6% | -39.2% | -50% | -85.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -73.8% | -92.2% | -73.6% | -57.1% |
| EPS Diluted | -2.53 | -138.65 | -353.59 | -184.09 |
| % Growth | 98.2% | 60.8% | -92.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |